Literature DB >> 25266991

The role of nitisinone in tyrosine pathway disorders.

Edward Lock1, Lakshminarayan R Ranganath, Oliver Timmis.   

Abstract

Nitisinone 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC), an effective herbicide, is the licensed treatment for the human condition, hereditary tyrosinaemia type 1 (HT-1). Its mode of action interrupts tyrosine metabolism through inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD). Nitisinone is a remarkable safe drug to use with few side effects reported. Therefore, we propose that it should be investigated as a potential treatment for other disorders of tyrosine metabolism. These include alkaptonuria (AKU), a rare disease resulting is severe, early-onset osteoarthritis. We present a case study from the disease, and attempts to use the drug both off-label and in clinical research through the DevelopAKUre consortium.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266991     DOI: 10.1007/s11926-014-0457-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  30 in total

1.  The nature of the defect in tyrosine metabolism in alcaptonuria.

Authors:  B N LA DU; V G ZANNONI; L LASTER; J E SEEGMILLER
Journal:  J Biol Chem       Date:  1958-01       Impact factor: 5.157

2.  Living with alkaptonuria.

Authors:  Simon Laxon; Lakshminarayan Ranganath; Oliver Timmis
Journal:  BMJ       Date:  2011-09-29

3.  Excess dietary tyrosine and corneal lesions.

Authors:  L F Rich; M E Beard; R P Burns
Journal:  Exp Eye Res       Date:  1973-10-10       Impact factor: 3.467

4.  Oxidation of homogentisic acid to ochronotic pigment in connective tissue.

Authors:  V G Zannoni; N Lomtevas; S Goldfinger
Journal:  Biochim Biophys Acta       Date:  1969-02-18

5.  Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.

Authors:  Edward A Lock; Peter Gaskin; Martin Ellis; William M Provan; Lewis L Smith
Journal:  Toxicol Appl Pharmacol       Date:  2006-03-31       Impact factor: 4.219

6.  Spontaneous tendon ruptures in alkaptonuria.

Authors:  R V Manoj Kumar; S Rajasekaran
Journal:  J Bone Joint Surg Br       Date:  2003-08

Review 7.  Recent advances in management of alkaptonuria (invited review; best practice article).

Authors:  Lakshminarayan R Ranganath; Jonathan C Jarvis; James A Gallagher
Journal:  J Clin Pathol       Date:  2013-03-13       Impact factor: 3.411

8.  Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy.

Authors:  J A Wolff; B Barshop; W L Nyhan; J Leslie; J E Seegmiller; H Gruber; M Garst; S Winter; K Michals; R Matalon
Journal:  Pediatr Res       Date:  1989-08       Impact factor: 3.756

9.  Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.

Authors:  M De Braekeleer; J Larochelle
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

10.  The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria.

Authors:  A M Taylor; A Boyde; P J M Wilson; J C Jarvis; J S Davidson; J A Hunt; L R Ranganath; J A Gallagher
Journal:  Arthritis Rheum       Date:  2011-12
View more
  11 in total

1.  Molecular docking analysis of nitisinone with homogentisate 1,2 dioxygenase.

Authors:  Narges Zolfaghari
Journal:  Bioinformation       Date:  2017-05-31

2.  Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

Authors:  Birgitta Olsson; Trevor F Cox; Eftychia E Psarelli; Johan Szamosi; Andrew T Hughes; Anna M Milan; Anthony K Hall; Jozef Rovensky; Lakshminarayan R Ranganath
Journal:  JIMD Rep       Date:  2015-03-13

3.  A robust bacterial assay for high-throughput screening of human 4-hydroxyphenylpyruvate dioxygenase inhibitors.

Authors:  Jessie Neuckermans; Alan Mertens; Dinja De Win; Ulrich Schwaneberg; Joery De Kock
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

4.  Activation of Tyrosine Metabolism in CD13+ Cancer Stem Cells Drives Relapse in Hepatocellular Carcinoma.

Authors:  Li Sun; Lin Zhang; Jun Chen; Chaoqun Li; Hongqin Sun; Jiangrong Wang; Hong Xiao
Journal:  Cancer Res Treat       Date:  2019-12-27       Impact factor: 4.679

5.  Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis.

Authors:  Marcos Sterkel; Lee R Haines; Aitor Casas-Sánchez; Vincent Owino Adung'a; Raquel J Vionette-Amaral; Shannon Quek; Clair Rose; Mariana Silva Dos Santos; Natalia García Escude; Hanafy M Ismail; Mark I Paine; Seth M Barribeau; Simon Wagstaff; James I MacRae; Daniel Masiga; Laith Yakob; Pedro L Oliveira; Álvaro Acosta-Serrano
Journal:  PLoS Biol       Date:  2021-01-26       Impact factor: 8.029

6.  Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products.

Authors:  Steve O'Hagan; Douglas B Kell
Journal:  Mar Drugs       Date:  2020-11-23       Impact factor: 5.118

7.  Downregulation of the tyrosine degradation pathway extends Drosophila lifespan.

Authors:  Andrey A Parkhitko; Divya Ramesh; Lin Wang; Dmitry Leshchiner; Elizabeth Filine; Richard Binari; Abby L Olsen; John M Asara; Valentin Cracan; Joshua D Rabinowitz; Axel Brockmann; Norbert Perrimon
Journal:  Elife       Date:  2020-12-15       Impact factor: 8.140

8.  EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

Authors:  L Schmidt; O Sehic; C Wild
Journal:  J Pharm Policy Pract       Date:  2021-04-28

9.  Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.

Authors:  Naser Honar; Nader Shakibazad; Zahra Serati Shirazi; Seyed Mohsen Dehghani; Soroor Inaloo
Journal:  Iran J Child Neurol       Date:  2017

Review 10.  Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).

Authors:  Anibh Martin Das
Journal:  Appl Clin Genet       Date:  2017-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.